12th Jun 2014 06:02
LONDON (Alliance News) - AstraZeneca PLC and Amgen Inc said late Wednesday that phase II study results of psoriatic arthritis drug brodalumab showed that the treatment showed significant improvement in clinical symptoms.
The results, which were published in the New England Journal of Medicine, and will be presented at the 2014 European League Against Rheumatism congress in June, also showed that many patients continued to improve and saw sustained improvements.
The companies said that the encouraging data from the study was why they had opted to continue developing brodalumab as a potential treatment for psoriatic arthritis.
?We?re encouraged that treatment with brodalumab significantly reduced clinical signs and joint symptoms, compared to placebo, and that similar degrees of disease improvement were seen in biologic-treated and biologic-naive patients with psoriatic arthritis," said the lead investigator of the study Phillip Mease, from the Swedish Medical Center and University of Washington.
The two companies have begin two Phase III studies for the treatment.
Shares in AstraZeneca closed up 1.2% at 4,400.00 Wednesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca